At the news
? BULLISHIMPACT 6/10 8-K filed May 26, 2026 at 07:05 ET
Olema Pharmaceuticals announced a clinical trial collaboration and supply agreement with Bayer to evaluate its novel KAT6 inhibitor, OP-3136, in combination with Bayer's NUBEQA (darolutamide) in a Phase 1b/2 study for metastatic castration-resistant prostate cancer (mCRPC). The study is expected to initiate in H2 2026, with Bayer supplying darolutamide and Olema leading the study. Olema retains full global commercial and marketing rights to OP-3136. This is the first clinical collaboration for OP-3136, providing validation and potential expansion into a new indication beyond breast cancer.
- Olema entered a clinical trial collaboration and supply agreement with Bayer to evaluate OP-3136 (KAT6 inhibitor) in combination with NUBEQA (darolutamide) in mCRPC.
- Phase 1b/2 study will enroll approximately 36 patients with mCRPC; expected to initiate in H2 2026.
- Bayer will supply darolutamide; Olema will lead the study and retain full global commercial and marketing rights to OP-3136.
- This is the first clinical collaboration for OP-3136, which is currently in a Phase 1 monotherapy study and being evaluated in combination with fulvestrant and palazestrant in ER+/HER2- metastatic breast cancer.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access